Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $0.43 to $0.47
• 50-Day Range: $0.27 to $0.71
• 52-Week Range: $0.24 to $1.35
• Volume: 687,420 shs
• Average Volume: 19.42 million shs
• Market Capitalization: $8.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biomerica.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomerica is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomerica is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.50% of the outstanding shares of Biomerica have been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 24.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.50% of the outstanding shares of Biomerica have been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 24.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for BMRA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

4 people have added Biomerica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.28% of the stock of Biomerica is held by institutions.

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed this year?

Biomerica's stock was trading at $0.3001 on January 1st, 2025. Since then, BMRA stock has increased by 47.0% and is now trading at $0.4412.
View the best growth stocks for 2025 here.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Tuesday, January, 14th. The company reported ($0.06) earnings per share for the quarter. Biomerica had a negative net margin of 100.52% and a negative trailing twelve-month return on equity of 90.19%.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 1/14/2025
• Today: 2/04/2025
• Next Earnings (Estimated): 4/10/2025
• Fiscal Year End: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMRA
• CUSIP: N/A
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 645-2111
• Fax: 949-553-1231
• Employees: 60
• Year Founded: 1971

Profitability

• EPS (Most Recent Fiscal Year): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,980,000.00
• Net Margins: -100.52%
• Pretax Margin: -100.31%
• Return on Equity: -90.19%
• Return on Assets: -64.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.17
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $5.41 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 1.13

Miscellaneous

• Outstanding Shares: 18,340,000
• Free Float: 15,586,000
• Market Cap: $8.09 million
• Optionable: Optionable
• Beta: -0.98